Seeking Alpha

Shares of Keryx Biopharmaceuticals (KERX) shed 2.2% premarket after taking on a number of...

Shares of Keryx Biopharmaceuticals (KERX) shed 2.2% premarket after taking on a number of downgrades from analysts. The cratering of shares this week following the failure of its Perifisone drug serves as a stark reminder of the great risk/reward tradeoff in the biotech/small pharma sector, according to VFC Stock House.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)